SpringerLink
Log in

Drug Therapy

  • Chapter
  • First Online:
Raynaud’s Phenomenon

  • 99 Accesses

Abstract

Raynaud’s phenomenon (RP) may warrant pharmacological treatment if there are significant symptoms not controlled by nonpharmacological treatment or complications. The principles of RP treatment are to decrease the frequency of attacks, lessen the duration of attacks, and to prevent or treat complications especially after failure of conservative treatment (avoiding cold, stress and other precipitators, and stop** smoking). In general, secondary RP is more severe than primary. The majority of patients with both primary and secondary RP do not require drug treatment. However, patients with the most severe RP, for example, patients with systemic sclerosis (SSc), usually require drug treatment. First-line drug treatment is initiation of dihydropyridine class of calcium channel blockers (CCBs), where the most studied is nifedipine. Achievable goals of treatment with CCBs may be a 30% reduction in frequency of attacks. Other CCBs could be considered such as amlodipine, felodipine, and nicardipine. If this class is not effective or not tolerated (due to side effects such as hypotension and peripheral edema), then in moderate to severe secondary RP, phosphodiesterase type 5 (PDE5) inhibitors are considered and/or prostacyclins such as intravenous iloprost. In mild RP, PDE5 inhibitors, losartan (an angiotensin II receptor blocker) or fluoxetine (a selective serotonin reuptake inhibitor) may be considered with some positive randomized controlled trial data to support their use. Topical nitrates may be helpful, but there can be dose dependent side effects such as headache and hypotension. Angiotensin-converting-enzyme inhibitors have mostly negative data and are not recommended. Most experts suggest treatment of uncomplicated moderate to severe RP using combinations of drugs. For example, adding a PDE5 inhibitor after obtaining a partial response with a CCB. When using combination treatment, the chances of hypotension are increased, so blood pressure must be monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 128.39
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 171.19
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pope J. Raynaud’s phenomenon (primary). Clin Evid. 2013;2013:1119.

    Google Scholar 

  2. Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology. 2015;54:2015–24.

    Article  CAS  PubMed  Google Scholar 

  3. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–39.

    Article  PubMed  Google Scholar 

  4. Fernandez-Codina A, Walker KM, Pope JE. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820–8.

    Article  CAS  PubMed  Google Scholar 

  5. Fernandez-Codina A, Canas-Ruano E, Pope JE. Management of Raynaud’s phenomenon in systemic sclerosis - a practical approach. J Scleroderma Relat Disord. 2019;4:102–10.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Panopoulos S, Chatzidionysiou K, Tektonidou MG, et al. Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Res Ther. 2020;22:56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sturgill MG, Seibold JR. Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr Opin Rheumatol. 1998;10:584–8.

    Article  CAS  PubMed  Google Scholar 

  8. Malamet R, Wise RA, Ettinger WH, et al. Nifedipine in the treatment of Raynaud’s phenomenon. Evidence for inhibition of platelet activation. Am J Med. 1985;78:602–8.

    Article  CAS  PubMed  Google Scholar 

  9. Allanore Y, Borderie D, Lemarechal H, et al. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med. 2004;116:595–600.

    Article  CAS  PubMed  Google Scholar 

  10. Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2016;2:CD002069. https://doi.org/10.1002/14651858.CD002069.pub5.

    Article  PubMed  Google Scholar 

  11. Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017;12:CD000467.

    PubMed  Google Scholar 

  12. Khouri C, Lepelley M, Bailly S, et al. Comparative efficacy and safety of treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis of randomised trials. Lancet Rheumatol. 2019;1:e237–46.

    Article  PubMed  Google Scholar 

  13. Herrick A. Raynaud’s phenomenon (secondary). BMJ Clin Evid. 2008;2008:1125.

    PubMed  PubMed Central  Google Scholar 

  14. Khanna PP, Maranian P, Gregory J, et al. The minimally important difference and patient acceptable symptom state for the Raynaud’s condition score in patients with Raynaud’s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69:588–91.

    Article  PubMed  Google Scholar 

  15. Wasan EK, Zhao J, Poteet J, et al. Development of a UV-Stabilized topical formulation of nifedipine for the treatment of Raynaud phenomenon and chilblains. Pharmaceutics. 2019;11:594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Moinzadah P, Riemekasten G, Siegert E, et al. Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol. 2016;43:66–74.

    Article  Google Scholar 

  17. Di Luigi L, Sgro P, Duranti G, et al. Sildenafil reduces expression and release of IL-6 and IL-8 induced by reactive oxygen species in systemic sclerosis fibroblasts. Int J Mol Sci. 2020;21:3161.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72:1696–9.

    Article  CAS  PubMed  Google Scholar 

  19. Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2021;5:CD006687.

    PubMed  Google Scholar 

  20. Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172:1182–4.

    Article  CAS  PubMed  Google Scholar 

  21. Roustit M, Gaia J, Gaget O, et al. On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. Ann Intern Med. 2018;169:694–703.

    Article  PubMed  Google Scholar 

  22. Wortsman X, Del Barrio-Diaz P, Meza-Romero R, et al. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: a randomized, double-blind, controlled pilot study. J Am Acad Dermatol. 2018;78:189–90.

    Article  PubMed  Google Scholar 

  23. Fernandez-Codina A, Kazem M, Pope JE. Possible benefit of tadalafil cream for the treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis. Clin Rheumatol. 2020;39:963–5.

    Article  PubMed  Google Scholar 

  24. Lund F. Percutaneous nitroglycerin treatment in cases of peripheral circulatory disorders, especially Raynaud’s disease. Acta Med Scand. 1948;131(Suppl 206):196–206.

    Article  CAS  PubMed  Google Scholar 

  25. Kleckner MS, Allen EV, Wakim KG. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud’s disease and Raynaud’s phenomenon: studies on blood flow and clinical manifestations. Circulation. 1951;3:681–9.

    Article  PubMed  Google Scholar 

  26. Herrick AL. Therapy: a local approach to Raynaud phenomenon. Nat Rev Rheumatol. 2009;5:246–7.

    Article  CAS  PubMed  Google Scholar 

  27. Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology. 2002;41:324–8.

    Article  CAS  PubMed  Google Scholar 

  28. Pintea Bentea G, Wauters A, Wautrecht JC, et al. Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients. Vasc Med. 2020;25:559–68.

    Article  CAS  PubMed  Google Scholar 

  29. Teh L-S, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol. 1995;34:636–41.

    Article  CAS  PubMed  Google Scholar 

  30. Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon. Arthritis Rheum. 2009;60:870–7.

    Article  CAS  PubMed  Google Scholar 

  31. Curtiss P, Schwager Z, Cobos G, et al. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2018;78:1110–8.

    Article  CAS  PubMed  Google Scholar 

  32. Qui Q, Chan T, Luen M, et al. Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review. Rheumatol Int. 2018;38:2209–16.

    Article  Google Scholar 

  33. Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome. A double-blind controlled trial. Lancet. 1983;1(8320):313–5.

    Article  CAS  PubMed  Google Scholar 

  34. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000953.

    Google Scholar 

  35. Martins P, Dourado E, Fonseca JE, Romão V, Resende C. The safety and persistence of intravenous iloprost in systemic sclerosis. ARP Rheumatol. 2022;1(2):122–8.

    PubMed  Google Scholar 

  36. Negrini S, Magnani O, Matucci-Cerinic M, Carignola R, Data V, Montabone E, Santaniello A, Adorni G, Murdaca G, Puppo F, Indiveri F, Della Rossa A, D’Ascanio A, Barsotti S, Giuggioli D, Ferri C, Lumetti F, Bosello SL, Canestrari G, Bellando Randone S, Bruni C, Guiducci S, Battaglia E, De Andres MI, Russo AA, Beretta L. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med. 2019;19(3):357–66.

    Article  CAS  PubMed  Google Scholar 

  37. Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M. Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum. 2019;48(4):686–93.

    Article  CAS  PubMed  Google Scholar 

  38. Bellando-Randone S, Bruni C, Lepri G, Fiori G, Bartoli F, Conforti ML, Moggi-Pignone A, Guiducci S, Giuggioli D, Colaci M, Spinella A, Ferri C, Matucci-Cerinic M. The safety of iloprost in systemic sclerosis in a real-life experience. Clin Rheumatol. 2018;37(5):1249–55.

    Article  CAS  PubMed  Google Scholar 

  39. Foti R, Visalli E, Amato G, Benenati A, Converso G, Farina A, Bellofiore S, Mulè M, Di Gangi M. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int. 2017;37(2):245–9.

    Article  PubMed  Google Scholar 

  40. Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35(9):1830–7.

    CAS  PubMed  Google Scholar 

  41. Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, Murphy E, Steinberg M. Oral iloprost as a treatment for Raynaud’s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis. 1995;54(3):197–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR. Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol. 1998;37(9):952–60.

    Article  CAS  PubMed  Google Scholar 

  43. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41(4):670–7.

    Article  CAS  PubMed  Google Scholar 

  44. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol. 1996;23(11):1917–20.

    CAS  PubMed  Google Scholar 

  45. Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, et al. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther. 2013;15:R54.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Seibold JR, Wigley FM, Schiopu E, et al. Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up. J Scleroderma Relat Disord. 2017;2:42–9.

    Article  Google Scholar 

  47. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud’s syndrome. Ann Rheum Dis. 1985;44(11):754–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Marasini B, Massarotti M, Bottasso B, Coppola R, Papa ND, Maglione W, Comina DP, Maioli C. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33(4):253–6.

    Article  CAS  PubMed  Google Scholar 

  49. Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol. 1999;47(5):137–43.

    CAS  PubMed  Google Scholar 

  50. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646–55.

    Article  CAS  PubMed  Google Scholar 

  51. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001;40(9):1038–43.

    Article  CAS  PubMed  Google Scholar 

  52. Brin MF, Burstein R. Botox (onabotulinumtoxinA) mechanism of action. Medicine. 2023;102(S1):e32372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum. 2012;41:599–603.

    Article  CAS  PubMed  Google Scholar 

  54. Ennis D, Ahmad Z, Anderson MA, Johnson SR. Botulinum toxin in the management of primary and secondary Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2021;35(3):101684.

    Article  PubMed  Google Scholar 

  55. Zhou Y, Yu Y, Bi S, Cen Y. Botulinum toxins for the treatment of Raynaud phenomenon: a systematic review with meta-analysis. J Clin Rheumatol. 2023;29(5):e92–9.

    Article  PubMed  Google Scholar 

  56. Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69(8):1661–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, Pistorius MA, Boulon C, Cogrel O, Warzocha U, Rivière S, Malloizel-Delaunay J, Servettaz A, Sassolas B, Viguier M, Monfort JB, Janique S, Vicaut E, BRASS Collaborators. Efficacy and safety of botulinum toxin in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2023;75(3):459–67.

    Article  CAS  PubMed  Google Scholar 

  58. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000956.

    Google Scholar 

  59. Wollersheim H, Thien T, Fennis J, van Elteren P, van Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther. 1986;40(2):219–25.

    Article  CAS  PubMed  Google Scholar 

  60. Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud’s phenomenon. Eur J Clin Pharmacol. 1983;24(3):421–3.

    Article  CAS  PubMed  Google Scholar 

  61. Le Quentrec P, Lefebvre ML. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud’s phenomenon: six-month follow-up. Angiology. 1991;42(4):289–95.

    Article  PubMed  Google Scholar 

  62. Grigg MJ, Nicolaides AN, Papadakis K, Wolfe JH. The efficacy of thymoxamine in primary Raynaud’s phenomenon. Eur J Vasc Surg. 1989;3(4):309–13.

    Article  CAS  PubMed  Google Scholar 

  63. Wesseling H, den Heeten A, Wouda AA. Sublingual and oral isoxsuprine in patients with Raynaud’s phenomenon. Eur J Clin Pharmacol. 1981;20(5):329–33.

    Article  CAS  PubMed  Google Scholar 

  64. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud’s phenomenon. Ann Pharmacother. 2006;40(11):1998–2002.

    Article  CAS  PubMed  Google Scholar 

  65. Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM. The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol. 1987;117(6):751–8.

    Article  CAS  PubMed  Google Scholar 

  66. Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Subjective and objective assessment of enalapril in primary Raynaud’s phenomenon. Br J Clin Pharmacol. 1991;31(4):477–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ. Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther. 1988;13(2):145–50.

    Article  CAS  PubMed  Google Scholar 

  68. Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56(11):3837–46.

    Article  CAS  PubMed  Google Scholar 

  69. Arosio E, Montesi G, Zannoni M, Paluani F, Lechi A. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud’s phenomenon. Angiology. 1989;40(7):633–8.

    Article  CAS  PubMed  Google Scholar 

  70. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630–8.

    Article  CAS  PubMed  Google Scholar 

  71. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011;15(40):1–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, Brook R, Kaplan MJ. Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol. 2003;92(11):1310–5.

    Article  CAS  PubMed  Google Scholar 

  73. Negrini S, Spanò F, Penza E, Rollando D, Indiveri F, Filaci G, Puppo F. Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients. Clin Exp Med. 2016;16(3):407–12.

    Article  CAS  PubMed  Google Scholar 

  74. van de Wal HJ, Wijn PF, van Lier HJ, Skotnicki SH. The effectiveness of ketanserin in patients with primary Raynaud’s phenomenon. A randomized, double blind, placebo controlled study. Int Angiol. 1987;6(3):313–22.

    PubMed  Google Scholar 

  75. Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ, Murray GD, Nielsen SL. International study of ketanserin in Raynaud’s phenomenon. Am J Med. 1989;87(3):264–8.

    Article  CAS  PubMed  Google Scholar 

  76. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000954.

    Google Scholar 

  77. Kato S, Kishiro I, Ohnuma N, Takasaki K, Okamoto S, Nakamoto T, et al. Suppressive effect of saprogrelate hydrochloride on Raynaud’s phenomenon and respiratory failure in patients with systemic sclerosis. Respirology. 2000;5:27–32.

    Article  CAS  PubMed  Google Scholar 

  78. Bounameaux HM, Hellemans H, Verhaege R. Digital pressure and flow measurement upon local cooling in Raynaud’s disease. Effect of naftidrofuryl. Int Angiol. 1986;5(1):39–44.

    CAS  PubMed  Google Scholar 

  79. Davinroy M, Mosnier M. Double-blind clinical evaluation of naftidrofuryl in Raynaud’s phenomenon. Sem Hôpitaux Paris. 1993;69:1322–6.

    Google Scholar 

  80. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.

    CAS  PubMed  Google Scholar 

  81. Sadik HY, Moore TL, Vail A, et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology. 2010;49(5):990–6.

    Article  CAS  PubMed  Google Scholar 

  82. Ladak K, J.E. Pope. A review of the effects of statins in systemic sclerosis. Semin Arthritis Rheum. 2016;45(6):698–705.

    Google Scholar 

  83. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet. 1990;336(8730):1530–3.

    Article  CAS  PubMed  Google Scholar 

  84. Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet. 1993;342(8863):80–3.

    Article  CAS  PubMed  Google Scholar 

  85. Shawket S, Dickerson C, Hazleman B, Brown MJ. Prolonged effect of CGRP in Raynaud’s patients: a double-blind randomised comparison with prostacyclin. Br J Clin Pharmacol. 1991;32(2):209–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol. 2021;177(7):785–90.

    Article  CAS  PubMed  Google Scholar 

  87. Evans RW. Raynaud’s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache. 2019;59(8):1360–4.

    Article  PubMed  Google Scholar 

  88. Bedrin K, Ailani J, Dougherty C. Raynaud’s phenomenon associated with calcitonin gene-related peptide receptor antagonists case report. Headache. 2022;62(10):1419–23.

    Article  PubMed  Google Scholar 

  89. Gérard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lantéri-Minet M, Drici MD. Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. 2022;23(1):53.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, Pittelkow MR, Mangold AR. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021;4(4):e217934.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Whitmore SE, Wigley FM, Wise RA. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud’s phenomenon. J Rheumatol. 1995;22(1):50–4.

    CAS  PubMed  Google Scholar 

  92. Sunderland GT, Belch JJF, Sturrock RD, Forbes CD, McKay AJ. A double blind randomised placebo controlled trial of Hexopal in primary Raynaud’s disease. Clin Rheumatol. 1988;7:46–9.

    Article  CAS  PubMed  Google Scholar 

  93. Murphy R. The effect of inositol nicotinate (Hexopal) in patients with Raynaud phenomenon – a placebo-controlled study. Clin Trials J. 1985;22:521–9.

    Google Scholar 

  94. Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology. 2010;49(3):583–7. https://doi.org/10.1093/rheumatology/kep413.

    Article  CAS  PubMed  Google Scholar 

  95. Phat TN, Luong VH, Minh VN, My LH, Phuong HT, Vinh NTH, Doanh LH. Bosentan versus nifedipine in the treatment of vasculopathy in systemic sclerosis patients: a randomized control trial. Asian Pac J Allergy Immunol. 2022. https://doi.org/10.12932/AP-070722-1406.

  96. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  97. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE, DUAL-1 Investigators; DUAL-2 Investigators. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975–88.

    Article  CAS  PubMed  Google Scholar 

  98. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 2004;50(12):3994–4001.

    Article  CAS  PubMed  Google Scholar 

  99. Herrick AL, Murray AK, Ruck A, Rouru J, Moore TL, Whiteside J, Hakulinen P, Wigley F, Snapir A. A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology. 2014;53(5):948–52.

    Article  CAS  PubMed  Google Scholar 

  100. Dompeling EC, Smit AJ. Assessment of pinacidil in patients with primary Raynaud’s phenomenon. VASA Suppl. 1992;34:34–7.

    CAS  PubMed  Google Scholar 

  101. Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res. 2012;64(6):925–9. https://doi.org/10.1002/acr.21622.

    Article  CAS  Google Scholar 

  102. Sandner P, Stasch J. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med. 2017;122:S1–9.

    Article  PubMed  Google Scholar 

  103. Rahaghi FF, Trivieri MG, Sahay S. The role of riociguat in combination therapies for pulmonary arterial hypertension. Respir Med. 2023;211:107196.

    Article  PubMed  Google Scholar 

  104. Ghofrani H-A, Galiè N, Grimminger F, Grűnig E, Humbert M, **g Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. NEJM. 2013;369:330–40.

    Article  CAS  PubMed  Google Scholar 

  105. Huntgeburth M, Kießling J, Weimann G, Wilberg V, Saleh S, Hunzelmann N, Rosenkranz S. Riociguat for the treatment of Raynaud’s phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT). Clin Drug Investig. 2018;38(11):1061–9.

    Article  CAS  PubMed  Google Scholar 

  106. Nagaraja V, Spino C, Bush E, Tsou PS, Domsic RT, Lafyatis R, Frech T, Gordon JK, Steen VD, Khanna D. A Multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther. 2019;21(1):202.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, de Oliveira PJ, Yao Z, Kramer F, Distler O. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020;79(5):618–25.

    Article  PubMed  Google Scholar 

  108. Hayoz D, Hengstler J, Noel B, Brunner HR. Vasopressin induces opposite changes in blood flow in the skin and the muscular circulation. Adv Exp Med Biol. 1998;449:447–9.

    Article  CAS  PubMed  Google Scholar 

  109. Hayoz D, Bizzini G, Noël B, Depairon M, Burnier M, Fauveau C, Rouillon A, Brouard R, Brunner HR. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud’s phenomenon. Rheumatology. 2000;39(10):1132–8.

    Article  CAS  PubMed  Google Scholar 

  110. Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology. 2009;48(7):791–5. https://doi.org/10.1093/rheumatology/kep039. Review, PMID: 1943343.

    Article  PubMed  Google Scholar 

  111. Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265–7.

    Article  PubMed  Google Scholar 

  112. Choi WS, Choi CJ, Kim KS, Lee JH, Song CH, Chung JH, Ock SM, Lee JB, Kim CM. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol. 2009;28(5):553–9. https://doi.org/10.1007/s10067-008-1084-9.

    Article  PubMed  Google Scholar 

  113. Sporbeck B, Mathiske-Schmidt K, Jahr S, Huscher D, Becker M, Riemekasten G, Taufmann I, Burmester GR, Pögel S, Reisshauer A. Effect of biofeedback and deep oscillation on Raynaud’s phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int. 2012;32(5):1469–73. https://doi.org/10.1007/s00296-011-1882-2.

    Article  PubMed  Google Scholar 

  114. Author. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160(8):1101–8.

    Article  Google Scholar 

  115. Kondo K, Noonan KM, Freeman M, Ayers C, Morasco BJ, Kansagara D. Efficacy of biofeedback for medical conditions: an evidence map. J Gen Intern Med. 2019;34(12):2883–93.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Daniels J, Pauling JD, Eccleston C. Behaviour change interventions for the management of Raynaud’s phenomenon: a systematic literature review. BMJ Open. 2018;8(12):e024528.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K, Bruckdorfer KR, Black CM. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology. 1999;38(4):309–15.

    Article  CAS  PubMed  Google Scholar 

  118. Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28(10):2257–62.

    CAS  PubMed  Google Scholar 

  119. Correa MJ, Mariz HA, Andrade LE, et al. Oral N-acetylcysteine in the treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Rev Bras Reumatol. 2014;54(6):452–8.

    Article  PubMed  Google Scholar 

  120. Herrick AL, Hollis S, Schofield D, et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol. 2000;18(3):349–56.

    CAS  PubMed  Google Scholar 

  121. Curtiss P, Schwager Z, Lo Sicco K, Franks AG. The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud’s phenomenon. J Eur Acad Dermatol Venereol. 2019;33(3):497–503.

    Article  CAS  PubMed  Google Scholar 

  122. Tucker AT, Pearson RM, Cooke ED. Benjamin N Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet. 1999;354(9191):1670–5.

    Article  CAS  PubMed  Google Scholar 

  123. Mavrikakis ME, Lekakis JP, Papamichael CM, Stamatelopoulos KS, Kostopoulos CC, Stamatelopoulos SF. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res. 2003;73(1):3–7.

    Article  CAS  PubMed  Google Scholar 

  124. DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989;86(2):158–64.

    Article  CAS  PubMed  Google Scholar 

  125. Malenfant D, Summers K, Seney S, McBain D, Petrlich L, Watson S, Vanderhoek L, Samadi N, Bonner A, Pope J. Results of a pilot randomized placebo-controlled trial in primary and secondary Raynaud’s phenomenon with St John’s Wort: detecting changes in angiogenic cytokines when RP improves. ISRN Rheumatol. 2011;2011:580704. https://doi.org/10.5402/2011/580704. PMID:22389797.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Zhang J, Hu J, He X, Meng Y, Chen G, Chen Z, Lü J, Li P. Effectiveness of Chinese herbal medicine for primary Raynaud’s phenomenon: a systematic review and meta-analysis of randomized controlled trials. J Tradit Chin Med. 2020;40(4):509–17.

    PubMed  Google Scholar 

  127. Eid AH, Maiti K, Mitra S, Chotani MA, Flavahan S, Bailey SR, Thompson-Torgerson CS, Flavahan NA. Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol. 2007;293(3):1955–61.

    Article  Google Scholar 

  128. Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW. Felson DT The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med. 1998;129(3):208–11.

    Article  CAS  PubMed  Google Scholar 

  129. Fardoun M, Mondello S, Kobeissy F, Eid AH. G protein estrogen receptor as a potential therapeutic target in Raynaud’s phenomenon. Front Pharmacol. 2022;13:1061374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Bartelink ML, Wollersheim H, Vemer H, Thomas CM, de Boo T, Thien T. The effects of single oral doses of 17 beta-oestradiol and progesterone on finger skin circulation in healthy women and in women with primary Raynaud’s phenomenon. Eur J Clin Pharmacol. 1994;46(6):557–60.

    Article  CAS  PubMed  Google Scholar 

  131. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Cyclofenil for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000955. Review. PMID: 10796397.

    Google Scholar 

  132. Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin N Am. 2005;31(1):177–86.

    Article  Google Scholar 

  133. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82(12):1555–7. A8

    Article  CAS  PubMed  Google Scholar 

  134. Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L. A controlled study of stanozolol in primary Raynaud’s phenomenon and systemic sclerosis. Ann Rheum Dis. 1991;50(1):41–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Dessein PH, Morrison RC, Lamparelli RD, van der Merwe CA. Triiodothyronine treatment for Raynaud’s phenomenon: a controlled trial. J Rheumatol. 1990;17(8):1025–8.

    CAS  PubMed  Google Scholar 

  136. Lau CS, McLaren M, Saniabadi A, Belch JJF. Increased whole blood platelet aggregation in patients with Raynaud’s phenomenon with or without systemic sclerosis. Scand J Rheumatol. 1993;22:97–101.

    Article  CAS  PubMed  Google Scholar 

  137. Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F, et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud’s phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol. 2001;30:290–6.

    Article  CAS  PubMed  Google Scholar 

  138. Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis. 2007;18(4):297–302.

    Article  PubMed  Google Scholar 

  139. Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, Chesebro JH, O’Fallon WM. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum. 1984;27(10):1137–43.

    Article  CAS  PubMed  Google Scholar 

  140. Destors JM, Gauthier E, Lelong S, Boissel JP. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud’s phenomenon. Angiology. 1986;37(8):565–9.

    Article  CAS  PubMed  Google Scholar 

  141. Rustin MH, Grimes SM, Kovacs IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P, Kirby JD. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud’s syndrome. Eur J Clin Pharmacol. 1984;27(1):61–5.

    CAS  PubMed  Google Scholar 

  142. Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud’s phenomenon. Am J Med. 1984;77(3):451–6.

    Article  CAS  PubMed  Google Scholar 

  143. Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud’s phenomenon. Clin Pharmacol Ther. 1984;36(3):369–73.

    Article  CAS  PubMed  Google Scholar 

  144. Tindall H, Tooke JE, Menys VC, Martin MF, Davies JA. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud’s phenomenon. Eur J Clin Investig. 1985;15(1):20–3.

    Article  CAS  Google Scholar 

  145. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol. 2000;18(4):499–502.

    CAS  PubMed  Google Scholar 

  146. Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19(4):212–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Haroon M, O’Gradaigh D, Foley-Nolan D. A case of Raynaud’s phenomenon in mixed connective tissue disease responding to rituximab therapy. Rheumatology. 2007;46(4):718–9.

    Article  CAS  PubMed  Google Scholar 

  148. Hor CG, Chen XL, Lin TS, Lu CH. Hsieh SC Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol. 2014;33(7):1019–20.

    Article  Google Scholar 

  149. Shabrawishi M, Albeity A, Almoallim H. Severe primary Raynaud’s disease treated with rituximab. Case Rep Rheumatol. 2016;2016:2053804.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK

    Ariane L. Herrick

  2. Division of Rheumatology, School of Medicine Johns Hopkins University, Baltimore, MD, USA

    Fredrick M. Wigley

  3. Division of Rheumatology, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada

    Janet Pope

Authors
  1. Ariane L. Herrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fredrick M. Wigley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janet Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariane L. Herrick .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University, Baltimore, MD, USA

    Fredrick M. Wigley

  2. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK

    Ariane L. Herrick

  3. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Nicholas A. Flavahan

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Herrick, A.L., Wigley, F.M., Pope, J. (2024). Drug Therapy. In: Wigley, F.M., Herrick, A.L., Flavahan, N.A. (eds) Raynaud’s Phenomenon. Springer, Cham. https://doi.org/10.1007/978-3-031-52581-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-52581-0_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-52580-3

  • Online ISBN: 978-3-031-52581-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation